早期子宫内膜癌保留生育功能治疗后复发的诊治
Diagnosis and management in patients with recurrent stage I endometrial cancer after primary fertility-preserving treatment

DOI: 10.6040/j.issn.1671-7554.0.2018.229

Keywords: 子宫内膜不典型增生,子宫内膜上皮内瘤变,子宫内膜癌,复发,保留生育功能治疗,
Endometrial cancer,Endometrial intraepithelial neoplasia,Atypical endometrial hyperplasia,Recurrence,Fertility-preserving therapy

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Rackow BW, Arici A. Endometrial cancer and fertility[J]. Curr Opin Obstet Gynecol, 2006, 18(3): 245-252.
[2]	Park JY, Lee SH, Seong SJ. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin[J]. Gynecol Oncol, 2013, 129(1): 7-11.
[3]	Signorelli M, Caspani G, Bonazzi C, et al. Fertility-sparing treatment in young women with EC or atypical complex hyperplasia: a prospective single-institution experience of 21 cases[J]. BJOG, 2009, 116(1): 114-118.
[4]	Navarria I, Usel M, Rapiti E, et al. Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment?[J]. Gynecol Oncol, 2009, 114(3): 448-451.
[5]	Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis[J]. Am J Obstet Gynecol, 2012, 207(4): 266.e1-12.
[6]	Baek JS, Lee WH, Kang WD, et al. Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: is it effective?[J] Obstetr Gynecol Sci, 2016, 59(1): 24-31.
[7]	Qin Y, Yu Z, Yang J, et al. Oral progestin treatment for early-stage endometrial cancer: a systematic review and meta-analysis[J]. Int J Gynecol Cancer, 2016, 26(6): 1081-1091.
[8]	Eftekhar Z, Izadi-Mood N, Yarandi F, et al. Efficacy of megestrol acetate(megace)in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients[J]. Int J Gynecol Cancer, 2009, 19(2): 249-252.
[9]	Lin G, Ng KK, Chang CJ, et al. Myometrial invasion in endometrial cancer: diagnostic accuracy of diffusion-weighted 3.0-T MR imaging-initial experience[J]. Radiol, 2009, 250(3): 784-792.
[10]	Sala E, Rockall AG, Freeman SJ, et al. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know[J]. Radiol, 2013, 266(3): 717-740.
[11]	Yamazawa K, Hirai M, Fujito A, et al. Fertility-preserving treatment with progestin and pathologic criteria to predict responses, in young women with EC[J]. Hum Reprod, 2007, 22(7): 1953-1958.
[12]	Corzo C, Barrientos Santillan N, Westin SN, et al. Updates on conservative management of endometrial cancer[J]. J Minim Invasive Gynecol, 2018, 25(2): 308-313.
[13]	Gonthier C, Trefoux-Bourdet A, Koskas M. Impact of conservative managements in young women with grade 2 or 3 endometial adenocarcinoma confined to the endometrium[J]. Int J Gynecol Cancer, 2017, 27(3): 493-499.
[14]	Kim YB, Holschneider CH, Ghosh K, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature[J]. Cancer, 1997, 79(2): 320-327.
[15]	Zhou H, Cao D, Yang J, et al. Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women[J]. Int J Gynecol Cancer, 2017, 27(6): 1178-1182.
[16]	曹冬焱,俞梅,杨佳欣,等.大剂量孕激素治疗早期子宫内膜癌及子宫内膜重度不典型增生患者的妊娠结局及相关因素分析[J].中华妇产科杂志, 2013, 48(7): 519-522. CAO Dongyan, YU Mei, YANG Jiaxin, et al. Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin[J]. Chin J Obstet Gynecol, 2013, 48(7): 519-522.
[17]	Pronin SM, Novikova OV, Andreeva JY, et al. Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential[J]. Int J Gynecol Cancer, 2015, 25(6): 1010-1014.
[18]	Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review[J]. Gynecol Oncol, 2004, 95(1): 133-138.
[19]	Kim SR, van der Zanden C, Ikiz H, et al. Fertility-sparing management using progestin for young women with endometrial cancer from a population-based study[J]. J Obstet Gynaecol Can, 2018, 40(3): 328-333.
[20]	Baker J, Obermair A, Gebski V, et al. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature[J]. Gynecol Oncol, 2012, 125(1): 263-270.
[21]	Yu M, Yang JX, Wu M, et al. Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium[J]. Fertil Steril, 2009, 92(6): 2122-2124.
[22]	Gotlieb WH, Beiner ME, Shalmon B, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer[J]. Obstet Gynecol, 2003, 102(4): 718-725.
[23]	Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women[J]. J Clin Oncol, 2007, 25(19): 2798-2803.
[24]	Perri T, Korach J, Gotlieb WH, et al. Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved[J]. Int J Gynecol Cancer, 2011, 21(1): 72-78.
[25]	Lee TS, Jung JY, Kim JW, et al. Feasibility of ovarian preservation in patients with early stage endometrial carcinoma[J]. Gynecol Oncol, 2007, 104(1): 52-57.

Full-Text